4//SEC Filing
Abingworth LLP 4
Accession 0000905718-22-000177
CIK 0001290149other
Filed
Jan 31, 7:00 PM ET
Accepted
Feb 1, 5:00 PM ET
Size
10.2 KB
Accession
0000905718-22-000177
Insider Transaction Report
Form 4
Abingworth LLP
10% Owner
Transactions
- Exercise of In-Money
Common Stock, $0.001 par value
2022-01-28$13.20/sh+287,471$3,794,617→ 1,164,127 total(indirect: See footnote) - Purchase
Common Stock, $0.001 par value
2022-01-31$27.00/sh+150,000$4,050,000→ 1,314,127 total(indirect: See footnote) - Exercise of In-Money
Series B Warrants (right to buy)
2022-01-28−287,471→ 0 total(indirect: See footnote)Exercise: $13.20From: 2020-01-22→ Common Stock (287,471 underlying)
Footnotes (2)
- [F1]The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F2]Each Series B warrant will expire on the 75th day anniversary of the Issuer's announcement of top-line data from its MOMENTUM Phase 3 clinical trial of momelotinib.
Documents
Issuer
Sierra Oncology, Inc.
CIK 0001290149
Entity typeother
IncorporatedUnited Kingdom
Related Parties
1- filerCIK 0001397144
Filing Metadata
- Form type
- 4
- Filed
- Jan 31, 7:00 PM ET
- Accepted
- Feb 1, 5:00 PM ET
- Size
- 10.2 KB